Drug Profile
Research programme: inflammatory disease therapy - Progen Pharmaceuticals
Latest Information Update: 24 Jul 2008
Price :
$50
*
At a glance
- Originator Cellgate
- Developer Progen Pharmaceuticals Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 22 Jul 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 09 Aug 2007 Preclinical trials in Inflammation in USA (unspecified route)